Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients
Joint Authors
Muhammadpour, Amir-Hooshang
Khayyat, Muhammad Hassanzade
Tafaghodi, Muhsin
Salari, Pooneh
Charkazi, Sumayyah
Shamsara, Jamal
Nazemian, Fatimah
Naghibi, Masih
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 25, Issue 1 (28 Feb. 2014), pp.73-78, 6 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2014-02-28
Country of Publication
Saudi Arabia
No. of Pages
6
Main Subjects
Topics
- Patients
- Diseases
- Anti-inflammatories
- Therapeutics
- Side effects
- Hemodialysis
- Blood
- Anemia
- Kidney failure
- Erythropoietin
- Pentoxifylline
Abstract EN
Use of recombinant human erythropoietin (rh-Epo) improves hemoglobin (Hgb) in 90–95% of the cases of anemia of chronic kidney disease (CKD).
However, it is known that proinflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alfa (TNF-α) and interleukin-1 (IL-1) suppress erythropoiesis, resulting in inadequate response to rh-Epo.
Pentoxifylline has been shown to have modulatory effects on the immune system.
This prospective study to evaluate the effect of pentoxyphylline on erythropoeisis was performed on 15 (eight males, seven females) clinically stable patients who had been on hemodialysis for at least six months with anemia (Hgb of <10.7 g/dL) unresponsive to rh-Epo despite high doses.
They were treated with 400 mg pentoxifylline tablets once daily for 12 weeks.
Hgb increased after one and two months of drug administration, but significant changes were observed in eight (53%) patients after three months (P <0.05).
Our study illustrates a probable new use for an old medicine.
Three months treatment with pentoxifylline was seen to increase Hgb significantly in rh-Epo-resistant patients.
More prospective studies with a larger sample size are needed to determine the inhibitory role of cytokines on hematopoiesis and exploring new drugs or new drug indications to overcome anemia in advanced renal failure.
American Psychological Association (APA)
Muhammadpour, Amir-Hooshang& Nazemian, Fatimah& Khayyat, Muhammad Hassanzade& Tafaghodi, Muhsin& Salari, Pooneh& Charkazi, Sumayyah…[et al.]. 2014. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation،Vol. 25, no. 1, pp.73-78.
https://search.emarefa.net/detail/BIM-356650
Modern Language Association (MLA)
Muhammadpour, Amir-Hooshang…[et al.]. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation Vol. 25, no. 1 (Jan. / Feb. 2014), pp.73-78.
https://search.emarefa.net/detail/BIM-356650
American Medical Association (AMA)
Muhammadpour, Amir-Hooshang& Nazemian, Fatimah& Khayyat, Muhammad Hassanzade& Tafaghodi, Muhsin& Salari, Pooneh& Charkazi, Sumayyah…[et al.]. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation. 2014. Vol. 25, no. 1, pp.73-78.
https://search.emarefa.net/detail/BIM-356650
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 78
Record ID
BIM-356650